Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil

Detalhes bibliográficos
Autor(a) principal: Holzmann,Iandra
Data de Publicação: 2018
Outros Autores: Tovo,Cristiane V., Minmé,Roseline, Leal,Mônica P., Kliemann,Michele P., Ubirajara,Camila, Aquino,Amanda A., Araujo,Bruna, Almeida,Paulo R.L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317
Resumo: ABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients.
id BSID-1_82d36cdb3cbf4bfcdf330e14d17f135e
oai_identifier_str oai:scielo:S1413-86702018000400317
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in BrazilSofosbuvirDaclatasvirSimeprevirDAASustained virological responseABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients.Brazilian Society of Infectious Diseases2018-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317Brazilian Journal of Infectious Diseases v.22 n.4 2018reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2018.06.004info:eu-repo/semantics/openAccessHolzmann,IandraTovo,Cristiane V.Minmé,RoselineLeal,Mônica P.Kliemann,Michele P.Ubirajara,CamilaAquino,Amanda A.Araujo,BrunaAlmeida,Paulo R.L.eng2018-10-09T00:00:00Zoai:scielo:S1413-86702018000400317Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2018-10-09T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
title Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
spellingShingle Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Holzmann,Iandra
Sofosbuvir
Daclatasvir
Simeprevir
DAA
Sustained virological response
title_short Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
title_full Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
title_fullStr Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
title_full_unstemmed Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
title_sort Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
author Holzmann,Iandra
author_facet Holzmann,Iandra
Tovo,Cristiane V.
Minmé,Roseline
Leal,Mônica P.
Kliemann,Michele P.
Ubirajara,Camila
Aquino,Amanda A.
Araujo,Bruna
Almeida,Paulo R.L.
author_role author
author2 Tovo,Cristiane V.
Minmé,Roseline
Leal,Mônica P.
Kliemann,Michele P.
Ubirajara,Camila
Aquino,Amanda A.
Araujo,Bruna
Almeida,Paulo R.L.
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Holzmann,Iandra
Tovo,Cristiane V.
Minmé,Roseline
Leal,Mônica P.
Kliemann,Michele P.
Ubirajara,Camila
Aquino,Amanda A.
Araujo,Bruna
Almeida,Paulo R.L.
dc.subject.por.fl_str_mv Sofosbuvir
Daclatasvir
Simeprevir
DAA
Sustained virological response
topic Sofosbuvir
Daclatasvir
Simeprevir
DAA
Sustained virological response
description ABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients.
publishDate 2018
dc.date.none.fl_str_mv 2018-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjid.2018.06.004
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.22 n.4 2018
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209244571238400